Published in Ann Oncol on July 05, 2010
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol (2014) 2.45
Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat (2012) 1.77
Inflammatory breast cancer: what we know and what we need to learn. Oncologist (2012) 1.41
Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med (2011) 1.15
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol (2013) 1.14
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer (2013) 1.11
Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res (2011) 1.07
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Locoregional therapy of locally advanced breast cancer: a clinical practice guideline. Curr Oncol (2015) 1.01
Inflammatory breast cancer: a clinical diagnosis. Singapore Med J (2014) 1.00
Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer (2013) 1.00
β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death Differ (2014) 1.00
Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol (2013) 0.99
EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res (2013) 0.96
Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. Breast Cancer Res Treat (2012) 0.96
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol (2013) 0.96
Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007. Cancer Epidemiol Biomarkers Prev (2011) 0.96
Extent of primary breast cancer surgery: standards and individualized concepts. Breast Care (Basel) (2012) 0.95
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol (2014) 0.94
Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res Treat (2011) 0.91
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat (2015) 0.90
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? Breast Cancer Res Treat (2011) 0.89
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat (2010) 0.89
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat (2011) 0.88
Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One (2015) 0.88
Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer. BMC Cancer (2012) 0.85
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. J Oncol (2013) 0.84
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget (2016) 0.83
Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat (2013) 0.82
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med (2013) 0.82
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol (2015) 0.82
Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer (2014) 0.82
Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer. Saudi Med J (2014) 0.81
Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res (2013) 0.81
(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2013) 0.80
¹⁸F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer. Eur J Nucl Med Mol Imaging (2013) 0.80
Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling. Sci Rep (2016) 0.80
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer (2016) 0.80
High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys (2015) 0.79
Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res (2015) 0.79
Prognostic significance of tumour stroma ratio in inflammatory breast cancer. Springerplus (2015) 0.78
In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene. J Cancer (2013) 0.78
Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. Onco Targets Ther (2014) 0.78
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget (2016) 0.78
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res (2014) 0.78
Demographic, clinical, pathological, molecular, treatment characteristics and outcomes of nonmetastatic inflammatory breast cancer in Morocco: 2007 and 2008. Exp Hematol Oncol (2014) 0.78
Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer (2015) 0.78
Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med (2014) 0.78
Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival. Int J Hyperthermia (2015) 0.78
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget (2016) 0.77
Breast reconstruction following prophylactic or therapeutic mastectomy for breast cancer: Recommendations from an evidence-based provincial guideline. Plast Surg (Oakv) (2014) 0.77
Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study. BMC Cancer (2016) 0.76
Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines. Clin Exp Metastasis (2012) 0.76
Does secondary inflammatory breast cancer represent post-surgical metastatic disease? Cancers (Basel) (2012) 0.76
Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget (2017) 0.76
Label noise in subtype discrimination of class C G protein-coupled receptors: A systematic approach to the analysis of classification errors. BMC Bioinformatics (2015) 0.76
Bevacizumab in HER2-negative inflammatory breast cancer. Oncoscience (2016) 0.75
The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) (2016) 0.75
Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach. ACS Med Chem Lett (2017) 0.75
Axillary high-grade B-cell non-Hodgkin lymphoma presenting under the guise of inflammatory breast carcinoma. Rev Bras Hematol Hemoter (2015) 0.75
Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control (2016) 0.75
Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst (2015) 0.75
Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. J Cancer (2016) 0.75
Authors' reply: Inflammatory breast cancer: a clinical diagnosis. Singapore Med J (2014) 0.75
Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides. J Clin Aesthet Dermatol (2015) 0.75
The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer. Sci Rep (2016) 0.75
Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer. Cancer Epidemiol (2015) 0.75
Systemic inflammatory response syndrome in a patient diagnosed with high grade inflammatory triple negative breast cancer: a case report of a potentially rare paraneoplastic syndrome. Exp Hematol Oncol (2016) 0.75
MARCKS protein overexpression in inflammatory breast cancer. Oncotarget (2017) 0.75
Incidence of inflammatory breast cancer in women, 1992-2009, United States. Ann Surg Oncol (2013) 0.75
A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples. PLoS One (2014) 0.75
Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus (2014) 0.75
Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer (2017) 0.75
EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget (2017) 0.75
Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. J Cancer (2017) 0.75
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget (2017) 0.75
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst (2005) 4.14
Rho GTPases are over-expressed in human tumors. Int J Cancer (1999) 3.70
Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst (1985) 2.95
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res (2000) 2.48
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol (2007) 2.05
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol (2004) 1.72
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res (2001) 1.65
A novel human xenograft model of inflammatory breast cancer. Cancer Res (1999) 1.61
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol (2006) 1.60
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (2004) 1.59
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol (2007) 1.54
Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer (1995) 1.51
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat (2005) 1.49
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol (2002) 1.47
The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.44
Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med (2005) 1.33
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat (2007) 1.31
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med (2009) 1.29
Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology (2002) 1.26
Inflammatory carcinoma of the breast. A pathologic definition. Cancer (1974) 1.19
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer (2003) 1.18
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.15
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res (2009) 1.12
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol (2004) 1.08
Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg (1994) 1.05
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg (2000) 1.05
High incidence of HER-2 positivity in inflammatory breast cancer. Breast (2004) 1.05
18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol (2004) 1.04
Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys (2003) 1.01
Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst (1993) 1.01
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat (2002) 0.97
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer (1999) 0.96
Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer (2006) 0.94
Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer (2008) 0.94
Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer (2004) 0.90
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer (2004) 0.90
Imaging in inflammatory breast carcinoma. Breast Dis (2006) 0.89
p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res (2004) 0.87
Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res (1992) 0.84
18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med (2005) 0.84
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer (2006) 0.84
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant (2004) 0.84
Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol (1982) 0.83
Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile? J Am Coll Surg (2000) 0.82
[High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]. Clin Ter (2007) 0.81
The role of simple skin biopsy in uncertain inflammatory carcinoma of the breast. Am Surg (1958) 0.79
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst (1985) 2.95
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol (2000) 2.73
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
Jejunal diverticulosis. A heterogenous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus. Gastroenterology (1983) 2.66
A new technique for sampling duodenal contents: demonstration of upper small-bowel pathogens. Am J Trop Med Hyg (1970) 2.63
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA (1995) 2.50
RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res (2000) 2.48
Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology (1978) 2.41
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
Factor concentrates for treatment of hemophilia: which one to choose? Blood (1989) 2.16
Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet (2000) 2.15
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res (2000) 2.13
A new function for platelets: IgE-dependent killing of schistosomes. Nature (1983) 2.11
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
The immunological response of CBA mice to Trypanosoma musculi. I. Initial control of the infection and the effect of T-cell deprivation. Clin Exp Immunol (1974) 1.87
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation (1973) 1.84
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol (2007) 1.83
The LS locus of pea encodes the gibberellin biosynthesis enzyme ent-kaurene synthase A. Plant J (1997) 1.82
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol (2012) 1.82
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol (2010) 1.81
Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer (1999) 1.81
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res (1998) 1.80
Distinct and redundant roles of the two protein kinase A isoforms Tpk1p and Tpk2p in morphogenesis and growth of Candida albicans. Mol Microbiol (2001) 1.79
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
The role of breast FNAC in diagnosis and clinical management: a survey of current practice. Cytopathology (2008) 1.75
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74
Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol (2001) 1.73
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer (1999) 1.68
Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology (1985) 1.67
Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev (1993) 1.66
Blood platelets and serum VEGF in cancer patients. Br J Cancer (1999) 1.66
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett (1999) 1.64
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood (1990) 1.64
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia (2001) 1.63
Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature (1984) 1.63
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology (1985) 1.60
Identification of a negative regulator of gibberellin action, HvSPY, in barley. Plant Cell (1998) 1.58
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (1999) 1.58
Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol (2001) 1.57
Pathology of neuromuscular disorders of the small intestine and colon. Gastroenterology (1987) 1.57
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol (2006) 1.55
Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer (2009) 1.55
Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol (2007) 1.54
Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer (2010) 1.54
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer (1997) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol (1990) 1.52
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51
Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med (1988) 1.51
Schistosoma induced squamous cell carcinoma of the bladder. Indian J Pathol Microbiol (2001) 1.47
Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation. Curr Genet (1998) 1.46
Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant (2011) 1.46
Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B. Ann Intern Med (1973) 1.46
Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer (2006) 1.46
High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol (2001) 1.45
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer (2004) 1.44
Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys (2001) 1.44
Severe pediatric head injury: myth, magic, and actual fact. Pediatr Neurosurg (1998) 1.43
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat (2004) 1.43
Hepatobiliary rhabdomyosarcoma in children: diagnostic radiology. Pediatr Radiol (1998) 1.42
Transfusion transmission of human T-lymphotropic virus types I and II: lessons to be learned from look-back investigations and implications for patient counseling. Transfusion (1993) 1.42
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium. Am J Hum Genet (2000) 1.41
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg (1998) 1.40
COX-2 involvement in breast cancer metastasis to bone. Oncogene (2007) 1.40
Coronary artery dosimetry in intact left breast irradiation. Cancer J (2001) 1.40
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant (2005) 1.39
n-3 fatty acids and cellular aspects of atherosclerosis. Arch Intern Med (1989) 1.39
Intestinal parasite infection in the Kampuchean refugee population 6 years after resettlement in Canada. J Infect Dis (1992) 1.39
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer (2011) 1.38
Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation. Bone Marrow Transplant (1995) 1.38
Benign giant cell tumor of bone with osteosarcomatous transformation ("dedifferentiated" primary malignant GCT): report of two cases. Skeletal Radiol (1997) 1.36